About
Zachary Sweeney is the Chief Scientific Officer at Denali. In this role, he supports the biology, discovery pharmacology, genomics, small molecule and biotherapeutic discovery groups. Before joining Denali, Zach was a director and scientific investigator at the Novartis Institutes for Biomedical Research. He also worked as a scientist and team leader at Genentech and Roche. His teams have contributed to the identification of more than a dozen candidate medicines for the treatment of neurodegenerative diseases, inflammatory diseases and infectious diseases, and six of these molecules have progressed into clinical studies. Zach has co-authored approximately 60 patent applications and 35 scientific articles. Zach graduated from Stanford University, received a Ph.D. in chemistry from the University of California, Berkeley, and completed a NIH-postdoctoral fellowship at Harvard University.
Position in the VCSift Database
- • 3,360 investors hold the CEO role in VCSift. Zach Sweeney is one of them.
- • 31 investors are based in South San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- South San Francisco, US
Contact Information
Find more investors like Zach
Search Investors